Compare with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NEULAND LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NEULAND LABS ALKEM LABORATORIES/
NEULAND LABS
 
P/E (TTM) x 22.4 49.3 45.3% View Chart
P/BV x 5.4 3.7 144.6% View Chart
Dividend Yield % 0.9 0.1 928.5%  

Financials

 ALKEM LABORATORIES   NEULAND LABS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
NEULAND LABS
Mar-20
ALKEM LABORATORIES/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs2,720754 360.9%   
Low Rs1,660247 671.4%   
Sales per share (Unadj.) Rs697.9594.5 117.4%  
Earnings per share (Unadj.) Rs96.112.6 760.9%  
Cash flow per share (Unadj.) Rs117.337.0 316.8%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.10.4 285.6%  
Book value per share (Unadj.) Rs515.2553.4 93.1%  
Shares outstanding (eoy) m119.5712.83 932.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.10.8 372.8%   
Avg P/E ratio x22.839.6 57.5%  
P/CF ratio (eoy) x18.713.5 138.1%  
Price / Book Value ratio x4.30.9 470.0%  
Dividend payout %26.015.8 164.3%   
Avg Mkt Cap Rs m261,8796,421 4,078.6%   
No. of employees `00014.31.3 1,117.9%   
Total wages/salary Rs m15,0551,236 1,218.5%   
Avg. sales/employee Rs Th5,822.65,949.4 97.9%   
Avg. wages/employee Rs Th1,050.5963.8 109.0%   
Avg. net profit/employee Rs Th802.0126.4 634.3%   
INCOME DATA
Net Sales Rs m83,4447,627 1,094.0%  
Other income Rs m1,04239 2,682.6%   
Total revenues Rs m84,4867,666 1,102.1%   
Gross profit Rs m14,7341,019 1,446.1%  
Depreciation Rs m2,528313 808.1%   
Interest Rs m651216 301.6%   
Profit before tax Rs m12,598529 2,380.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105367 300.9%   
Profit after tax Rs m11,493162 7,091.0%  
Gross profit margin %17.713.4 132.2%  
Effective tax rate %8.869.4 12.6%   
Net profit margin %13.82.1 648.1%  
BALANCE SHEET DATA
Current assets Rs m54,9605,152 1,066.8%   
Current liabilities Rs m32,4333,576 906.9%   
Net working cap to sales %27.020.7 130.7%  
Current ratio x1.71.4 117.6%  
Inventory Days Days80105 75.7%  
Debtors Days Days7291 79.4%  
Net fixed assets Rs m32,7103,969 824.2%   
Share capital Rs m239129 185.3%   
"Free" reserves Rs m61,3686,971 880.4%   
Net worth Rs m61,6077,100 867.7%   
Long term debt Rs m1,592774 205.8%   
Total assets Rs m99,43312,310 807.8%  
Interest coverage x20.43.5 589.7%   
Debt to equity ratio x00.1 23.7%  
Sales to assets ratio x0.80.6 135.4%   
Return on assets %12.23.1 397.9%  
Return on equity %18.72.3 817.2%  
Return on capital %21.09.5 221.6%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,0615,187 309.7%   
Fx outflow Rs m2,4831,593 155.9%   
Net fx Rs m13,5783,594 377.8%   
CASH FLOW
From Operations Rs m5,851573 1,020.4%  
From Investments Rs m-7,414-487 1,522.9%  
From Financial Activity Rs m792-55 -1,444.3%  
Net Cashflow Rs m-73133 -2,242.6%  

Share Holding

Indian Promoters % 66.9 36.3 184.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 63.7 51.9%  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 63.7 -  
Shareholders   68,381 12,705 538.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades 279 Points Lower; Indicates Gap-Down Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a negative note today. At 8:10 am, it was trading down by 279 points, or 1.9% lower at 14,900 levels.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 26, 2021 09:46 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS